Page last updated: 2024-08-24

fluorodeoxyglucose f18 and bibw 2992

fluorodeoxyglucose f18 has been researched along with bibw 2992 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Carbonetti, G; Carlin, SD; Chiosis, G; de Stanchina, E; Divilov, V; Gomes-DaGama, EM; Holland, JP; Janjigian, YY; Lewis, JS; Viola-Villegas, N	1
Li, J; Ma, J; Wang, Y; Wang, Z; Wu, X	1
Bianchi, R; Bossi, P; Canevari, S; Clement, PM; Coropciuc, R; Crippa, F; De Cecco, L; de Saint Aubain, N; Duprez, T; Fortpied, C; Guzzo, M; Hauben, E; Lalami, Y; Lemort, M; Lhommel, R; Lia, M; Licitra, LF; Liu, Y; Machiels, JP; Menis, J; Quattrone, P; Quiriny, M; Schmitz, S	1

Reviews

1 review(s) available for fluorodeoxyglucose f18 and bibw 2992

Article	Year
Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2017, Volume: 65, Issue:5 Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome	2017

Article

Year

Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2017, Volume: 65, Issue:5

Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome

2017

Trials

1 trial(s) available for fluorodeoxyglucose f18 and bibw 2992

Article	Year
Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN). Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 04-01, Volume: 29, Issue:4 Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Biomarkers; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Positron-Emission Tomography; Preoperative Care; Squamous Cell Carcinoma of Head and Neck	2018

Article

Year

Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN).

Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 04-01, Volume: 29, Issue:4

Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Biomarkers; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Positron-Emission Tomography; Preoperative Care; Squamous Cell Carcinoma of Head and Neck

2018

Other Studies

1 other study(ies) available for fluorodeoxyglucose f18 and bibw 2992

Article	Year
Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:6 Topics: Afatinib; Animals; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cell Transformation, Neoplastic; Fluorodeoxyglucose F18; Humans; Mice; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radiochemistry; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome	2013

Article

Year

Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:6

Topics: Afatinib; Animals; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cell Transformation, Neoplastic; Fluorodeoxyglucose F18; Humans; Mice; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radiochemistry; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome

2013